Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats

Current Cancer Drug Targets

Volumn 10, Issue 2, 2010, Pages 229-241

  Yu, Lunyin ^a   Garg, Hari G ^a   Li, Boyangzi ^b   Linhardt, Robert J ^b   Hales, Charles A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Antitumor; Butanoylated; Heparin; Lung cancer; Mice; Rats

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN P53; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; HEART; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER; LUNG CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; TOXICITY TESTING;

ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BUTANOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; HEPARIN; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; RATS; RATS, NUDE; SMALL CELL LUNG CARCINOMA; TUMOR CELLS, CULTURED;

EID: 77950645414     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791054176     Document Type: Article

References (71)

1. Marcum, J. A. The origin of the dispute over the discovery of heparin. J. Hist. Med. Allied Sci. 2000, 55, 37-66.
2. Garg, H. G.; Roughley, P. J.; Hales, C. A. Heparin as a potential therapeutic agent to reverse vascular remodeling Proteoglycans in Lung Disease. In Proteoglycans in Lung Disease. Garg, H. G.; Hales, C. A. and Linhardt, R. J., Ed. Marcel Dekker, Inc; New York, NY 2002, pp. 377-398.
3. Petitou, M.; Coudert, C.; Level, M.; Lormeau, J. -C.; Zuber, M.; Simenel, C.; Fournier, J. -P.; Choay, J. Selectively O-acylated glycosaminoglycan derivatives. Carbohydr. Res. 1992, 236, 107-119.
4. Lazo-Langner, A.; Goss, G. D.; Spaans, J. N.; Rodger, M. A. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J. Thromb. Haemost. 2007, 5(4), 729-737.
5. Sasisekharan, R.; Shriver, Z.; Venkataraman, G.; Narayanasami, U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2002, 2(7), 521-528.
6. Klerk, C. P.; Smorenburg, S. M.; Otten, H. M.; Lensing, A. W.; Prins, M. H.; Piovella, F.; Prandoni, P.; Bos, M. M.; Richel, D. J.; van Tienhoven, G.; Bulle, H. R. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 2005, 23(10), 2130-2135.
7. Engelberg, H. Actions of heparin that may affect the malignant process. Cancer 1999, 85(2), 257-272.
8. Niers, T. M.; Klerk, C. P.; DiNisio, M.; Van Noorden, C. J.; Buller, H. R; Reitsma, P. H.; Richel, D. J. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit. Rev. Oncol. Hematol. 2007, 61(3), 195-207.
9. Gao, Y.; Wei, M.; Zheng, S.; Ba, X.; Hao, S.; Zeng, X. Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to P-selectin. J. Cancer Res. Clin. Oncol. 2006, 132(4), 257-264.
10. Hasan, J.; Shnyder, S. D.; Clamp, A. R.; McGown, A. T.; Bicknell, R.; Presta, M.; Bibby, M.; Double, J.; Craig, S.; Leeming, D.; Stevenson, K.; Gallagher, J. T.; Jayson, G. C. Heparin octasaccharides inhibit angiogenesis in vivo. Clin. Cancer Res. 2005, 11(22), 8172-8179.
11. Karti, S. S.; Ovali, E.; Ozgur, O.; Yilmaz, M.; Sonmez, M.; Ratip, S.; Ozdemir, F. Induction of apoptosis and inhibition of growth of human hepatoma HepG2 cells by heparin. Hepatogastroenterology 2003, 50(54), 1864-1866.
12. Pross, M.; Lippert.; H.; Misselwitz, F.; Nestler, G.; Kruger, S.; Langer, H.; Halangk, W.; Schulz, H. U. Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadenocarcinoma cells in rats after laparoscopy. Thromb. Res. 2003, 110(4), 215-220.
13. Amirkhosravi, A.; Mousa, S. A.; Amaya, M.; Francis, J. L. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J. Thromb. Haemost. 2003, 1(9), 1972-1976.
14. Mason, H. R.; Nowak, R. A.; Morton, C. C.; Castellot, J. J., Jr. Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells. Am. J. Pathol. 2003, 162(6), 1895-1904.
15. Lee, D. Y.; Kim, S. K.; Kim, Y. S.; Son, D. H.; Nam, J. H.; Kim, I. S.; Park, R. W.; Kim, S. Y.; Byun, Y. Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate. J. Control. Release 2007, 118(3), 310-317.
16. Lapierre, F.; Holme, K.; Lam, L.; Tressler, R. J.; Storm, N.; Wee, J.; Stack, R. J.; Castellot, J.; Tyrrell, D. J. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 1996, 6(3), 355-366.
17. Yoshitomi, Y.; Nakanishi, H.; Kusano, Y.; Munesue, S.; Oguri, K.; Tatematsu, M.; Yamashina, I.; Okayama, M. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett. 2004, 207(2), 165-174.
18. Balzarotti, M.; Fontana, F.; Marras, C.; Boiardi, A.; Croci, D.; Ciusani, E.; Salmaggi, A. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol. Res. 2006, 16(5), 245-250.
19. Icli, F.; Akbulut, H.; Utkan, G.; Yalcin, B.; Dincol, D.; Isikdogan, A.; Demirkazik, A.; Onur, H.; Cay, F.; Buyukcelik, A. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J. Surg. Oncol. 2007, 95(6), 507-512.
20. Mousa, S. A.; Linhardt, R.; Francis, J. L.; Amirkhosravi, A. Antimetastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb. Haemost. 2006, 96(6), 816-821.
21. Smorenburg, S. M.; Van Noorden, C. J. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev. 2001, 53(1), 93-105.
22. Kragh, M.; Binderup, L.; Vig Hjarnaa, P. J.; Bramm, E.; Johansen, K. B.; Frimundt, Petersen, C. Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol. Rep. 2005, 14(1), 99-104.
23. Garg, H. G.; Joseph, P. A.; Yoshida, K.; Thompson, B. T.; Hales, C. A. Antiproliferative role of 3-O-sulfate glucosamine in heparin on cultured pulmonary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 1996, 224(2), 468-473.
24. Garg, H. G.; Joseph, P. A.; Thompson, B. T.; Hales, C. A.; Toida. T.; Imanari, T.; Capila, I.; Linhardt, R. J. Effect of fully sulfated glycosaminoglycans on pulmonary artery smooth muscle cell proliferation. Arch. Biochem. Biophys. 1999, 371(2), 228-233.
25. Garg, H. G.; Thompson, B. T.; Hales, C. A. Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2000, 279(5), L779-L789.
26. Longas, M. O.; Garg, H. G.; Trinkle-Pereira, J. M.; Hales, C. A. Heparin antiproliferative activity on bovine pulmonary artery smooth muscle cells requires both N-acetylation and N-sulfonation. Carbohydr. Res. 2003, 338(3), 251-256.
27. Garg, H. G.; Yu, L.; Hales, C. A.; Toida, T.; Islam, T.; Linhardt, R. J. Sulfation patterns in heparin and heparan sulfate: effects on the proliferation of bovine pulmonary artery smooth muscle cells. Biochim. Biophys. Acta 2003, 1639(3), 225-231
28. Garg, H. G.; Hales, C. A.; Yu, L.; Butler, M.; Islam, T.; Xie, J.; Linhardt, R. J. Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecularweight heparin derivative. Carbohydr. Res. 2006, 341(15), 2607-2612.
29. Barzu, T.; Desmouliere, A.; Herbert, J. M.; Level, M.; Herault, J. P.; Petitou, M.; Lormeau, J. C.; Gabbiani, G.; Pascal, M. O-acylated heparin derivatives with low anticoagulant activity decrease proliferation and increase alpha-smooth muscle actin expression in cultured arterial smooth muscle cells. Eur. J. Pharmacol. 1992, 19(2), 225-233.
30. Stoeltzing, O.; McCarty, M. F.; Wey, J. S.; Fan, F.; Liu, W.; Belcheva, A.; Bucana, C. D.; Semenza, G. L.; Ellis, L. M. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl. Cancer Inst. 2004, 96(12), 946-956.
31. Scala, S.; Giuliano, P.; Ascierto, P. A.; Ierano, C.; Franco, R.; Napolitano, M.; Ottaiano, A.; Lombardi, M. L.; Luongo, M.; Simeone, E.; Castiglia, D.; Mauro, F.; De Michele, I.; Calemma, R.; Botti, G.; Caraco, C.; Nicoletti, G.; Satriano, R. A.; Castello, G. Human melanoma metastases express functional CXCR4. Clin. Cancer Res. 2006, 12(8), 2427-2433.
32. Phillips, R. J.; Burdick, M. D.; Lutz, M.; Belperio, J. A.; Keane, M. P.; Strieter, R. M. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med. 2003, 167(12), 1676-1686.
33. Yu, L.; Quinn, D. A.; Garg, H. G.; Hales, C. A. Deficiency of the NHE1 gene prevents hypoxia-induced pulmonary hypertension and vascular remodeling. Am. J. Respir. Crit. Care Med. 2008, 177(11), 1276-1284.
34. Yu, L.; Quinn, D. A.; Garg, H. G.; Hales, C. A. Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice. Circ. Res. 2005, 97, 937-945.
35. Folkman, J.; Langer, R.; Linhardt, R. J.; Haudenschild, C.; Taylor, S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983, 221(4612), 719-725.
36. Jung, S. P.; Siegrist, B.; Wade, M. R.; Anthony, C. T.; Woltering, E. A. Inhibition of human angiogenesis with heparin and hydrocortisone. Angiogenesis 2001, 4(3), 175-186.
37. Presta, M.; Leali, D.; Stabile, H.; Ronca, R.; Camozzi, M.; Coco, L.; Moroni, E.; Liekens, S.; Rusnati, M. Heparin derivatives as angiogenesis inhibitors. Curr. Pharm. Des. 2003, 9(7), 553-566.
38. Debergh, I.; Van Damme, N.; Pattyn, P.; Peeters, M.; Ceelen, W. P. The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model. Br. J. Cancer 2010 Feb 2. [Epub ahead of print].
39. Bobek, V.; Kovarik, J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed. Pharmacother. 2004, 58(4), 213-219.
40. Zacharski, L. R.; Loynes, J. T. The heparins and cancer. Curr. Opin. Pulm. Med. 2002, 8(5), 379-382.
41. Borsig, L.; Wong, R.; Feramisco, J.; Nadeau, D. R.; Varki, N. M.; Varki, A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. USA 2001, 98(6), 3352-3357.
42. Kenessey, I.; Simon, E.; Futosi, K.; Bereczky, B.; Kiss, A.; Erdödi, F.; Gallagher, J. T.; Tímár, J.; Tóvári, J. Antimigratory and antimetastatic effect of heparin-derived 4-18 unit oligosaccharides in a preclinical human melanoma metastasis model. Thromb. Haemost. 2009, 102(6), 1265-1273.
43. Wu, W. K.; Shin, V. Y.; Ye, Y. N.; Wong, H. P.; Huang, F. Y.; Hui, M. K.; Lam, E. K.; Cho, C. H. Heparin increases human gastric carcinoma cell growth. Anticancer Res. 2006, 26(1A), 439-443.
44. Cui, Z. Y.; Park, M. J.; Lee, J.; Ahn, J. S.; Ahn, M. J.; Seo, S. W.; Park, J. W.; Byun, Y.; Park, K. Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model. Cancer Res. Treat. 2009, 41(2), 80-86.
45. Bitan, M.; Mohsen, M.; Levi, E.; Wygoda, M. R.; Miao, H. Q.; Lider, O.; Svahn, C. M.; Ekre, H. P.; Ishai-Michaeli, R.; Bar- Shavit, R. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin. Isr. J. Med. Sci. 1995, 31(2-3), 106-118.
46. Wei, M.; Tai, G.; Gao, Y.; Li, N.; Huang, B.; Zhou, Y.; Hao, S.; Zeng, X. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J. Biol. Chem. 2004, 279(28), 29202-29210.
47. Bobek, V.; Boubelik, M.; Fiserova, A.; L'uptovcova, M.; Vannucci, L.; Kacprzak, G.; Kolodzej, J.; Majewski, A. M.; Hoffman, R. M. Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer 2005, 47(2), 215-223.
48. Sandal, T. Molecular aspects of the mammalian cell cycle and cancer. Oncologist 2002, 7(1), 73-81.
49. Israels, E. D.; Israels, L. G. The cell cycle. Oncologist 2000, 5(6), 510-513.
50. Brambilla, C.; Fievet, F.; Jeanmart, M.; de Fraipont, F.; Lantuejoul, S.; Frappat, V.; Ferretti, G.; Brichon, P. Y.; Moro-Sibilot, D. Early detection of lung cancer: role of biomarkers. Eur. Respir. J. Suppl. 2003, 39, 36s-44s.
51. Gorgoulis, V. G.; Zacharatos, P.; Mariatos, G.; Kotsinas, A.; Bouda, M.; Kletsas, D.; Asimacopoulos, P. J.; Agnantis, N.; Kittas, C.; Papavassiliou, A. G. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J. Pathol. 2002, 198(2), 142-156.
52. Linhardt, R. J. Heparin-induced cancer cell death. Chem. Biol. 2004, 11, 420-422.
53. Yu, M. K.; Lee, D. Y.; Kim, Y. S.; Park, K.; Park, S. A.; Son, D. H.; Lee, G. Y.; Nam, J. H.; Kim, S. Y.; Kim, I. S.; Park, R. W.; Byun, Y. Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy. Pharm Res. 2007, 24(4), 705-714.
54. Li, H. L.; Ye, K. H.; Zhang, H. W.; Luo, Y. R.; Ren, X. D.; Xiong, A. H.; Situ, R. Effect of heparin on apoptosis in human nasopharyngeal carcinoma CNE2 cells. Cell Res. 2001, 11(4), 311-315.
55. Jackson, R. J.; Adnane, J.; Coppola, D.; Cantor, A.; Sebti, S. M.; Pledger, W. J. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 2002, 21(55), 8486-8497.
56. Gao, H.; Ouyang, X.; Banach-Petrosky, W.; Borowsky, A. D.; Lin, Y.; Kim, M.; Lee, H.; Shih, W. J.; Cardiff, R. D.; Shen, M. M.; Abate-Shen, C. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 2004, 101(49), 17204-17209.
57. Hayashi, H.; Ogawa, N.; Ishiwa, N.; Yazawa, T.; Inayama, Y.; Ito, T.; Kitamura, H. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 2001, 34(1), 59-65.
58. Horiuchi, A.; Nikaido, T.; Ya-Li, Z.; Ito, K.; Orii, A.; Fujii, S. Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27. Mol. Hum. Reprod. 1999, 5(2), 139-145.
59. Yatabe, Y.; Masuda, A.; Koshikawa, T.; Nakamura, S.; Kuroishi, T.; Osada, H.; Takahashi, T.; Mitsudomi, T.; Takahashi, T. p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res. 1998, 58(5), 1042-1047.
60. Masuda, A.; Osada, H.; Yatabe, Y.; Kozaki, K.; Tatematsu, Y.; Takahashi, T.; Hida, T.; Takahashi, T.; Takahashi, T. Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments. Am. J. Pathol. 2001, 158(1), 87-96.
61. Murphy, J. W.; Cho, Y.; Sachpatzidis, A.; Fan, C.; Hodsdon, M. E.; Lolis, E. Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J. Biol. Chem. 2007, 282(13), 10018-10027.
62. Burger, J. A.; Kipps, T. J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107(5), 1761-1767.
63. Veldkamp, C. T.; Peterson, F. C.; Pelzek, A. J.; Volkman, B. F. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci. 2005, 14(4), 1071-1081.
64. Mellor, P.; Harvey, J. R.; Murphy, K. J.; Pye, D.; O'Boyle, G.; Lennard, T. W.; Kirby, J. A.; Ali, S. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br. J. Cancer 2007, 97(6), 761-768.
65. Mehta, S. A.; Christopherson, K. W.; Bhat-Nakshatri, P.; Goulet, R. J., Jr.; Broxmeyer, H. E.; Kopelovich, L.; Nakshatri, H. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene 2007, 26(23), 3329-3337.
66. Moskovits, N.; Kalinkovich, A.; Bar, J.; Lapidot, T.; Oren, M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 2006, 66(22), 10671-10676.
67. Schimanski, C. C.; Bahre, R.; Gockel, I.; Müller, A.; Frerichs, K.; Hörner, V.; Teufel, A.; Simiantonaki, N.; Biesterfeld, S.; Wehler, T.; Schuler, M.; Achenbach, T.; Junginger, T.; Galle, P. R.; Moehler, M. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br. J. Cancer 2006, 95(2), 210-217.
68. Khan, M. Z.; Shimizu, S.; Patel, J. P.; Nelson, A.; Le, M. T.; Mullen-Przeworski, A.; Brandimarti, R.; Fatatis, A.; Meucci, O. Regulation of neuronal P53 activity by CXCR 4. Mol. Cell Neurosci. 2005, 30(1), 58-66.
69. Khan, M. Z.; Brandimarti, R.; Shimizu, S.; Nicolai, J.; Crowe, E.; Meucci, O. The chemokine CXCL12 promotes survival of postmitotic neurons by regulating Rb protein. Cell Death Differ. 2008, 15(10), 1663-1672.
70. Khan, M. Z.; Brandimarti, R.; Musser, B. J.; Resue, D. M.; Fatatis, A.; Meucci, O. The chemokine receptor CXCR4 regulates cell-cycle proteins in neurons. J. Neurovirol. 2003, 9(3), 300-314.
71. Chen, Z.; Jing, Y.; Song, B.; Han, Y.; Chu, Y. Chemically modified heparin inhibits in vitro L-selectin-mediated human ovarian carcinoma cell adhesion. Int. J. Gynecol. Cancer 2009, 19(4), 540-546.